MedTrace Logo

Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites

NCT03315910 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 807

Last updated 2025-11-24

No results posted yet for this study

Summary

This study is to help determine the most effective type or combination of treatments to offer patients seeking lung cancer screening who are smokers to help them reduce the number of cigarettes they smoke, or quit smoking. The investigators long term goal is to increase the benefits of lung cancer screening by providing a blue print of best practices for screening sites to deliver tobacco treatment to their patients who are smokers, in a way that does not add burden to screening site staff and increases the chances of patients quitting smoking.

Conditions

  • Smoking Cessation

Interventions

BEHAVIORAL

Motivational Interviewing (MI)

two counseling sessions

DRUG

Nicotine Replacement Therapy (NRT)

receive 6 weeks of NRT patch with dosing dependent upon reported baseline cigarettes per day

DRUG

Nicotine Lozenge

6 packs of NRT 2mg lozenge

BEHAVIORAL

Message Framing

health communication literature and quitting messages

OTHER

saliva sample

saliva samples from those reporting abstinence and analyze samples

Sponsors & Collaborators

Principal Investigators

  • Jamie Ostroff, PhD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-10
Primary Completion
2026-10-31
Completion
2026-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03315910 on ClinicalTrials.gov